[go: up one dir, main page]

WO1999051261A1 - Utilisation therapeutique de l'urocortine et de polypeptides analogues - Google Patents

Utilisation therapeutique de l'urocortine et de polypeptides analogues Download PDF

Info

Publication number
WO1999051261A1
WO1999051261A1 PCT/GB1999/001056 GB9901056W WO9951261A1 WO 1999051261 A1 WO1999051261 A1 WO 1999051261A1 GB 9901056 W GB9901056 W GB 9901056W WO 9951261 A1 WO9951261 A1 WO 9951261A1
Authority
WO
WIPO (PCT)
Prior art keywords
ucn
crh
ischaemia
cardioprotective
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1999/001056
Other languages
English (en)
Inventor
Anastasis Stephanou
Bhawan Brar
Richard Knight
David Latchman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University College London
Original Assignee
University College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University College London filed Critical University College London
Priority to AU33403/99A priority Critical patent/AU3340399A/en
Publication of WO1999051261A1 publication Critical patent/WO1999051261A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2228—Corticotropin releasing factor [CRF] (Urotensin)

Definitions

  • the present invention relates to the use of urocortin, a 40 amino acid peptide, and derivatives thereof .
  • Urocortin (Ucn) has been cloned from both rat midbrain and human placental cDNA libraries (Vaughan, J., Donaldson, C, Bittencourt J. et al . Urocortin, a mammalian neuropeptide related to fish urotensin 1 and to corticotropin-releasing factor (CRH) . Nature. 1995: 378: 287-292; Donaldson, C.J., Sutton, S. ., Perrin, M.H. et al . Cloning and characterisation, of human urocortin. Endocrinology. 1996: 137: 2167-2170). Ucn is sometimes called corticotensin.
  • the human Ucn nucleotide sequence is predicted to encode a 124 amino acid protein comprising a 80 amino acid precursor and a 40 amino acid mature peptide (Donaldson, C.J., Sutton, S.W., Perrin, M. et al . Cloning and characterisation of human urocortin - Erratum. Endocrinology. 1996: 137: 3896).
  • the deduced mature rat and human peptides share 95% identity at the amino acid level, and rat Ucn shares 45% sequence identity with rat CRH.
  • the term "Urocortin” and the abbreviation "Ucn” are always used herein to refer to the mature peptide.
  • CRH-R1 Two distinct receptor genes for the CRH family of polypeptides, including Ucn, have been identified. Both encode seven transmembrane domain proteins and are functionally coupled to adenylate cyclase. The first, CRH-R1, was cloned from pituitary and brain (Chen, R., Lewis, K.A., Perrin, M.H., Vale, .W. Expression cloning -2 - of human corticotropm-releasmg factor receptor. Proc. Natl. Acad. Sci. USA. 1993: 90: 8967-8971; Chang, C, Pearse, R., O'Connell, S., Rosenfeld, M.G. Identification of a seven transmembrane helix receptor for corticotropm releasing factor and sauvagme m mammalian brain. Neuron. 1993: 11: 1187-1195).
  • CRH-R2 and ⁇ Two splice variants of a second receptor, CRH-R2 and ⁇ , which differ m their N-termmal domains, have also been isolated.
  • CRH-R2 ⁇ has been isolated from brain (Lovenberg, T.W., Liaw, C. ., Grigoriadis, D.E. et al . Cloning and characterisation of a functionally distinct corticotropm-releasmg factor receptor subtype from rat brain. Proc. Natl. Acad. Sci. USA.
  • CRH-R2 ⁇ has been isolated from heart, brain and lung (Lovenberg et al , 1995; Kishimoto, T., Pearse, R.V., Lm, C.R., Rosenfeld, M.G. A sauvagme/corticotropm- releas g factor receptor expressed heart and skeletal muscle. Proc. Natl. Acad. Sci. USA. 1995: 92: 1108- 1112) .
  • CRH and Ucn bind to and stimulate adenylate cyclase activity of the different receptor subtypes to different degrees with CRH-R2 ⁇ having roughly lOx higher affinity for Ucn.
  • Ucn mRNA and immunoreactivity are largely confined to the midbra Ed ger- estphal nucleus and the lateral superior olive, though weaker signals are found elsewhere.
  • Ucn mRNA is also present m the pituitary and Ucn peptide can stimulate the secretion of Adrenocorticotropm (ACTH) by anterior pituitary corticoctroph cells.
  • Adrenocorticotropm Adrenocorticotropm
  • Ucn CRH-bmd g protein
  • Ucn may act as a neurotransmitter involved in the innervation of the ciliary ganglion and in the processing of auditory signals.
  • Ucn also causes more pronounced and sustained falls in mean arterial blood pressure than CRH in vi vo, consistent with the higher affinity of the CRH-R2 ⁇ receptor found in the heart for Ucn. It is also a more potent inhibitor than CRH of the oedema following thermal injury to the rat paw, again consistent with Ucn being an endogenous ligand for CRH-R2 receptors.
  • Ucn is released from cultures of primary cardiac myocytes in response to ischaemic injury and that antagonists to the receptors of the CRH peptide family inhibit the protective effect of ischaemic conditioned media. Further, we have detected endogenous Ucn expression within the rat heart. We have shown that Ucn mRNA levels change following thermal injury to cardiac myocytes and that Ucn protects cardiac myocytes from cell death induced by hypoxia. Additionally, we have shown that Ucn protects isolated perfused hearts ex vivo .
  • the present invention provides: - use of urocortin, or a cardioprotective derivative thereof, in the manufacture of a medicament for use in the treatment of cardiac ischaemia; a method for the treatment of a patient who has suffered a cardiac ischaemia, which method comprises the step of administering to the patient a therapeutically effective amount of urocortin, or a cardioprotective derivative thereof; and an agent for treating cardiac ischaemia comprising urocortin or a cardioprotective derivative thereof.
  • Figure 1 shows the densitometric analysis of Ucn expression relative to that of glyceraldehyde-3-phosphate dehydrogenase (G3PDH) in H9c2 cells at various times after exposure to 42°C heat shock for 20 min;
  • G3PDH glyceraldehyde-3-phosphate dehydrogenase
  • Figure 2 shows the protective effects of 10 "8 M Ucn on 6 hours hypoxic exposure of primary cardiac myocytes. Cell death was assessed by trypan blue uptake (left hand figure) and by lactic dehydrogenase (LDH) release (right hand figure) ;
  • FIG. 3a Cultures of neonatal rat ventricular myocytes were treated with purified recombinant human CRH-BP (known to bind CRH and CRH-like peptides including urocortin) 24 hours before exposure to 6 hours of lethal ischaemia.
  • CRH-BP known to bind CRH and CRH-like peptides including urocortin
  • the untreated cells released 0.41 ⁇ 0.01 released activity and 16.19% of these cells were permeable to trypan blue. The experiments have been repeated three times to confirm the data.
  • Figure 4 Conditioned media from myocytes exposed to a two hour ischaemic insult protect fresh cardiac myocytes from lethal ischaemia in comparison to untreated cells as assessed by both LDH release (*p ⁇ 0.05) in comparison to untreated cells exposed to ischaemia.
  • Figure 6 A 2 hour ischaemic insult of cardiac myocytes transfected with the Ucn promoter containing the C/EBP (CCAAT/enhancer-binding protein) consensus site ligated upstream of a luciferase reporter results in a 2- fold increase in reporter activity.
  • C/EBP CCAAT/enhancer-binding protein
  • Ischaemic cardiac myocytes also show significant increases in expression of the C/EBP transcription factors C/EBP ⁇ (NF-IL6; approximately 4-fold) and C/EBP ⁇ (NF-IL6 ⁇ ; approximately 10-fold) , consistent with these enhancers being at least partially responsible for the increased expression of Ucn in ischaemic cardiac myocytes.
  • the invention is concerned with the use of Ucn or a cardioprotective derivative thereof to treat cardiac ischaemia.
  • the Ucn is typically human Ucn, in particular the 40 amino acid mature human peptide.
  • the full human Ucn amino acid sequence including the precursor sequence is shown in SEQ ID NOS: 1 and 2 (Genbank accession number U43177) .
  • the mature peptide is Asp-83 to Val-122 inclusive.
  • a cardioprotective derivative is a derivative which protects cardiac myocytes from cell death. It can thus reduce cell death induced by ischaemia in cardiac myocytes. This may be determined in vi tro by the following procedure: cardiac myocytes are incubated with a test polypeptide (test cardiac myocytes) ; ischaemia is induced by thermal stress, hypoxia or the use of a specific ischaemic buffer in the test cardiac myocytes and in control cardiac myocytes that - 6- have not been incubated with the test polypeptide; the respective proportions of the test cardiac myocytes that die as a result of the ischaemic challenge and of the control cardiac myocytes that die as a result of the ischaemic challenge are determined; and the ability of the test polypeptide to reduce cell death attributable to the challenge is thus assessed.
  • test cardiac myocytes test cardiac myocytes
  • ischaemia is induced by thermal stress, hypoxia or the use of a specific ischaemic buffer in the test cardiac myocytes and in control cardiac myocytes that
  • the proportions of the test and control cardiac myocytes that die by apoptosis and necrosis as a result of the ischaemic challenge may be determined.
  • a polypeptide is cardioprotective if it is able to reduce death of the test cardiac myocytes by 30% or more, for example 40% or more or 50% or more, with respect to the control cardiac myocytes. For example, there is a 50% reduction in cell death if 80% of the control cardiac myocytes and 40% of the test cardiac myocytes die as a result of the ischaemic challenge.
  • a cardioprotective derivative reduces cell death by 60% or more or 70% or more.
  • a cardioprotective derivative may bind to CRH-BP.
  • a cardioprotective derivative typically possesses an amino acid sequence that is substantially homologous to that of human Ucn.
  • the term derivative is taken to encompass allelic variants and species homologues .
  • An allelic variant is a variant which occurs naturally in a human and which will function in a substantially similar manner to human Ucn. In particular, it has cardioprotective activity.
  • a species homologue is a functionally equivalent polypeptide which occurs naturally in another species. Such a homologue may occur in animals such as mammals (e.g. rats or -7- rabbits), especially primates, pigs, sheep, cows or goats. Within any one species, a homologue may exist as several allelic variants.
  • Allelic variants and species homologues can be obtained using standard procedures.
  • a human Ucn nucleotide sequence can be used to probe libraries made from mammalian cells to obtain clones encoding the allelic or species variants.
  • the clones can be manipulated by conventional techniques to identify a polypeptide of the invention which can then be produced by recombinant or synthetic techniques known per se .
  • Preferred species homologues include primate, procine, ovine, bovine or caprine species homologues.
  • sequence of human Ucn or of allelic variants and species homologues can be modified to provide a suitable polypeptide.
  • One or more amino acid substitutions may be made, for example 1, 2, 3 or 4 or more, for example up to 10 substitutions may be made provided that the modified polypeptide retains cardioprotective activity.
  • Conservative substitutions may be made, for example according to the Table below. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other:
  • Alternative modifications include one or more amino acid deletion, rearrangement or extension.
  • An extension at the N-terminal and/or C-terminal may be provided.
  • the length of each extension may be relatively short, for example from 1 to 10 or from 3 to 6 amino acid residues. Alternatively the length of each extension may be much longer, for example from 10 to 200 or from 30 to 100 amino acid residues.
  • Any suitable extension may be provided, provided the resulting polypeptide is non- toxic, or at least suitable for use in animals of humans, and is cardioprotective. The length of each extension may thus serve as a carrier sequence.
  • a fusion protein may thus be provided.
  • a modified polypeptide is at least 70% homologous to the amino acid sequence of human Ucn, for example to the mature human Ucn amino acid sequence shown in SEQ ID NOS: 1 and 2 from Asp-83 to Val-122. There may be at least 80%, at least 90% or at least 95% homology. Methods of measuring protein homology are well known in the art and it will be well understood by those of skill in the art that in the present context, homology is calculated on the basis of amino acid identity (sometimes referred to as "hard homology") . Generally homology is calculated over a region of at least 20, preferably at least 30, for example 35 or more contiguous amino acids.
  • the cardioprotective derivative of Ucn may be a cardioprotective fragment of human Ucn, an allelic variant or species homologue thereof, or of a cardioprotective modified version of human Ucn or an allelic variant or species homologue thereof.
  • the fragment may be from 6, for example from 8 or from 10, to 15, for example to 20 or to 25, amino acids long.
  • a cardioprotective fragment may be identified using standard procedures. These may involve fragmentation of a polypeptide such as human Ucn using proteolytic enzymes or chemical agents and then determining the ability of - 9- each fragment to protect cardiac myocytes from cell death induced by ischaemia. Alternatively, the DNA encoding a polypeptide such as human Ucn may be fragmented by restriction enzyme digestion or other well-known techniques and then introduced into an expression system to produce fragments (optionally fused to a carrier polypeptide) . Again, the cardioprotective ability of the resulting fragments can be assessed.
  • Another approach is to chemically synthesise short peptide fragments, for example from 6 to 20 amino acids long) which cover the entire sequence of a full-length polypeptide such as human Ucn with each peptide overlapping the adjacent peptide. This overlap can be from 1 to 10 amino acids.
  • Each peptide is then assessed for its cardioprotective ability.
  • sequence homologies may be studied to identify a candidate motif that may be associated with cardioprotection. Such a prediction may then be tested by producing an appropriate polypeptide and assessing its ability to protect against cell death induced by ischaemia in cardiac myocytes.
  • the cardioprotective fragment may also be provided with the N-terminal and/or C-terminal extension.
  • the length of each extension may be relatively short, for example from 1 to 10 or from 3 to 6 amino acid residues. Alternatively the length of each extension may be much longer, for example from 10 to 200 or from 30 to 100 amino acid residues.
  • Any suitable extension may be provided, provided the resulting polypeptide is non- toxic, or is at least suitable for use in animals and humans, and is cardioprotective. The extension may thus serve as a carrier and/or targetting sequence.
  • the fragment may thus be presented as a fusion protein.
  • a polypeptide for use in the invention may be prepared by chemical synthesis.
  • a polypeptide may be built up from single amino acids and/or preformed - 1 0- peptides of two or more amino acids in the order of the sequence of the desired polypeptide. Solid-phase or solution methods may be employed. The resultant polypeptide may be converted into a pharmaceutically acceptable salt if desired.
  • the amino acid sequence of the desired polypeptide is built up sequentially from the C-terminal amino acid which is bound to an insoluble resin.
  • the desired peptide When the desired peptide has been produced, it is cleaved from the resin.
  • the desired polypeptide may again be built up from the C-terminal amino acid. The carboxy group of this acid remains blocked throughout by a suitable protecting group, which is removed at the end of the synthesis.
  • each amino acid added to the reaction system typically has a protected amino group and an activated carboxy group. Functional side-chain groups are protected too. After each step in the synthesis, the amino protecting group is removed. Side-chain functional groups are generally removed at the end of the synthesis.
  • the resultant polypeptide may then be converted into a pharmaceutically acceptable salt. It may be converted into an acid addition salt with an organic or inorganic acid. Suitable acids include acetic, succinic and hydrochloric acid. Alternatively, the polypeptide may be converted into a carboxylic acid salt such as the ammonium salt or an alkali metal salt such as the sodium or potassium salt.
  • a polypeptide for use in the invention may also be prepared by recombinant DNA methodologies.
  • a DNA sequence encoding the polypeptide is provided.
  • An expression vector is prepared which incorporates the DNA sequence and which is capable of expressing the - 1 1 - polypeptide when provided in a suitable host.
  • the DNA sequence is located between translation start and stop signals in the vector.
  • Appropriate transcriptional control elements are also provided, in particular a promoter for the DNA sequence and a transcriptional termination site.
  • the DNA sequence is provided in the correct frame such as to enable expression of the peptide to occur in a host compatible with the vector.
  • the vector may be a plasmid.
  • a bacterial or yeast host may be used.
  • the resulting polypeptide that is expressed can then be isolated and purified using standard techniques.
  • a polypeptide of the invention is used to treat cardiac ischaemia.
  • the polypeptides protect against necrotic and/or apoptotic cell death. They can therefore be used to treat myocardial ischaemia.
  • Myocardial ischaemia occurs when the heart muscle does not receive an adequate blood supply and is thus deprived of necessary levels of oxygen and nutrients.
  • the most common cause of myocardial ischaemia is atherosclerosis, causing blockages in the blood vessels (coronary arteries) that provide blood flow to the heart muscle.
  • the ischaemia may be attributable to low cardiac output, angina, clot formation or an arterial spasm.
  • a therapeutically effective amount of the polypeptide is administered to a patient, typically to a human patient, in need of such treatment.
  • the polypeptide can thus alleviate the ischaemia.
  • the polypeptide is typically administered by injection.
  • the polypeptide may be administered by intravenous or intramuscular injection, or orally provided it can be protected from the acid environment in the stomach. In emergencies it may be injected directly into the heart or into blood about to flow into the - 12 - heart.
  • the timing of administration of the polypeptide should be determined by medical personnel, but generally should occur as soon as possible after an ischaemic episode has been detected or is suspected of having taken place, for example within four hours of such an episode.
  • the amount of polypeptide that is given to a patient will depend upon a variety of factors including the nature of the patient under treatment and the severity of the condition under treatment. Typically, however, from 5 to 1000 mg of polypeptide may be given, for example from 10 to 500 mg. The exact dose will be determined by the medical personnel attending to the patient.
  • a polypeptide is formulated for administration with a pharmaceutically acceptable carrier or diluent.
  • a pharmaceutically acceptable carrier or diluent Any carrier or diluent suitable for a pharmaceutical composition and suitable for the selected route of administration may be employed.
  • Water for injection or physiological saline, for example phosphate-buffered saline, may be used for a formulation intended for injection.
  • Oral formulations can include such normally employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate and the like.
  • Capsules, tablets and pills may be provided with an enteric coating comprising, for example, Eudragit "S”, Eudragit "L”, cellulose acetate or hydroxypropylmethyl cellulose .
  • the H9c2 rat embryonic cardiac myoblast cell line was obtained from the ATCC (Rockville, Maryland, US) and was maintained in continuous culture in Dulbecco's - 13 - odified Eagles medium containing 10% foetal calf serum.
  • Primary Sprague Dawley rat myocyte cultures were obtained from pups less than 2 days old and were cultured as described previously (Simpson P, Savion S. Differentiation of rat myocytes in single cell cultures with and without proliferating nonmyocardial cells. Cross-striations, ultrastructure and chronotropic response to isoprotenol. Circ. Res. 1982: 50: 101-116). Brains were obtained from normal adult Sprague Dawley rats.
  • RNA extraction and Reverse Transcription were assessed using Trypan blue uptake and by the release of lactic dehydrogenase using a commercially available kit (Sigma, Poole, GB) .
  • H9c2 cells were thermally shocked by exposing them to 42°C for 20 minutes, after which they were returned to a 37°C incubator. Cell pellets were recovered at the times indicated in the Results, and stored at 80°C for RNA extraction.
  • Primary myocyte cultures were rendered hypoxic by exposure to an atmosphere of 5% C0 2 and 95% argon for 6 hours in a tissue culture chamber.
  • PCR Polymerase Chain Reaction
  • cDNAa were amplified in a reaction volume of 50 ⁇ l containing 200 uM final concentrations of mixed dNTPs, 2 mM MgCl 2 , 0.5 ⁇ M primers and 1.5 units of Taq polymerase (all reagents from Promega, Southampton, GB) .
  • Primers - 14 - for Ucn and the housekeeping gene, glyceraldehyde-3- phosphate dehydrogenase (G3PDH) were designed using the OLIGO 4.0 programme.
  • Amplification was performed on a Perkin Elmer 4800 thermal cycler for 35 cycles on settings of 94°C for 45 seconds, 64°C for 1 minute 30 seconds (58°C for G3PDH) and 72°C for 1 minute 30 seconds .
  • G3PDH AAG GTC GGA GTC AAC GGA TTT and AAG GTG GAG GAG TGG GTG TCG
  • Ucn (forward) GGC TGC GGC GGC GAA TGT GGT;
  • Amplification products were electrophoresed through 1.5% agarose gels containing ethidium bromide and visualised under an ultra violet transilluminator (Genetic Research Instrumentation, Dunmow, Essex, GB) . Bands of the predicted sizes were excised and the DNA purified using the Geneclean II kit (BIO 101 Inc, Vista, California, US) . Restriction digestion was performed for 18 hours at 37°C using Bam HI and Pst 1 (Promega, Hampshire, GB) , and the products were separated on a 2% ethidium bromide-stained agarose gel. Sequencing was performed using the dye terminator cycle sequencing method and the two reverse Ucn PCR primers.
  • Electrophoresis through 1.5% agarose gels revealed that PCR products of the expected 196 and 329 bp had been amplified from mRNA prepared frpm primary cardiac myocyte cultures and whole rat brain. Identical amplification products were also obtained from the H9c2 cell line. No Ucn product was amplified under the same or similar conditions from a bronchial epithelial and a neuroblastoma cell line.
  • the Ucn amplification products each contained a restriction site for Bam HI at position 168 and for Pst 1 at position 279 as determined from an electrophorogram of restriction digests.
  • Bam HI generated a 304 bp product and Pst 1 generated products of 137 and 192 bp .
  • a predicted 25 bp Bam HI product was not visible on the gel. Similar digestion fragments were obtained with the 329 bp product from rat brain and primary cardiac myocytes.
  • rat cardiac myocytes express Ucn mRNA, that the level of expression is increased by thermal shock and that Ucn protects cardiac myocytes from cell death induced by hypoxia.
  • Hypoxia induces both necrotic and apoptotic forms of cell death in cardiac myocytes, although hypoxia is associated more with necrosis and reperfusion than with apoptosis.
  • the Ucn-mediated reduction in LDH release observed here suggests that Ucn is protecting against necrotic cell death.
  • CRH is particularly associated with the hypothalamic response to physical and psychological stress.
  • the data reported here suggests that the related peptide, Ucn, can fulfil a similar role in mediating the response of cardiac myocytes to cellular stress.
  • the only CRH receptor found in the heart is CRH-R2 ⁇ which has at least lOx higher affinity for Ucn than CRH, both in terms of binding affinity and in the induction of cAMP . This suggests that endogenous Ucn may be the preferred ligand -17- for cardiac CRH receptor.
  • Ventricular myocytes isolated from the hearts of neonatal rats (Sprague Dawley) that were less than 2 days old were cultured as described previously (Simpson, P., Savion S., 1982) with the following modifications. After collagenase digestion the cells were pre-planted m medium consisting of DMEM (1000 mg glucose/L GIBCO), 1 mMol/L L-glutamme, 100 U/ml penicillm/streptomycm (GIBCO BRL) supplemented with 15% (v/v) fetal calf serum on 10cm tissue culture dishes. Pre-platmg of the cell suspension for 30 minutes allows contaminating fibroblasts to attach and the myocytes remain free within the culture media.
  • DMEM 1000 mg glucose/L GIBCO
  • 1 mMol/L L-glutamme 100 U/ml penicillm/streptomycm
  • GIBCO BRL U/ml penicillm/
  • the cardiac myocyte cell suspension was transferred onto six-well (3cm) gelatin coated plates (Falcon) at a density of 10 5 cells per well.
  • This plating system yields cell cultures that are more than 95% myocytes as determined by indirect staining with a monoclonal mouse antibody to Desmm (Wu, C.F., Bishopric, N.H., Pratt, R.E. Atrial nat ⁇ uretic peptide induces apoptosis in neonatal rat cardiac myocytes. J. Biol. Chem. 1997; 272 (23): 14860-6).
  • the cell media was replenished with the above media containing reduced FCS at 1% (v/v) for an additional 24 hours before experimentation (hereafter referred to as growth medium) .
  • growth medium 1% (v/v) for an additional 24 hours before experimentation.
  • a confluent monolayer of spontaneously beating myocytes was formed.
  • Preconditioned media was obtained from the cells by incubating 1 ml of the following control buffer; 137mM CaCl 2 , 3.8 mM KC1, 0.49 mM MgCl 2 , 0.9 mM CaCl 2 .2H20, 4 mM HEPES (pH 7.4) with the cells with the cells at 37°C in the ischaemic chamber for 2 hours.
  • the media was removed, centrifuged at 1000 rpm for 10 minutes and the supernatant incubated with fresh cells, in the presence and absence of 10 ⁇ 8 M a helical
  • CRH(9-41) CRH-binding protein (25 ⁇ g/ml) and ⁇ helical CRH(9-41) (0, 1, 10, 10000 nM) was added to untreated cells for 24 hours prior to exposure to lethal ischaemia. Lethal simulated ischaemia and determination of cardiocvte viability
  • LDH activity released from the cardiocytes was assessed using a spectrophotometric assay kit (Sigma) .
  • PBS phosphate buffered saline
  • Sibco-BRL trypsinised for 2 minutes in 0.25 mg/ml trypsin in versene
  • Cells were centrifuged, the supernatant aspriated and the cardiocytes resuspended in 100 ⁇ l of PBS. Following addition of an equal volume of 0.8% trypan blue in PBS, 250 cells were scored 3 times per plate of cells using a haemocytometer .
  • Ucn is synthesised as a precursor which is subsequently cleaved to yield the 40 amino acid mature peptide.
  • whole cell extracts were prepared in SDS-PAGE sample buffer and aliquots containing equal protein concentrations were separated on gradient polyacrylamide gels. Separated proteins were Western blotted onto nitrocellulose membranes and probed with a Ucn-specific antibody (Santa Cruz Biotechnology, Santa Cruz, CA) . Membranes were washed in PBS/0.05% Tween and incubated with a peroxidase conjugated anti-goat antibody (Santa Cruz) followed by detection using the enhanced chemiluminescence kit (ECL, Amersham) .
  • ECL enhanced chemiluminescence kit
  • the cells were returned to a normoxic environment of 21% 0 2 , 5% C0 2 at 37°C for 24 hours before harvesting for luciferase activity.
  • the cells were harvested with 1 mM EDTA and lysed with three cycles of freeze-thawing.
  • Assays for luciferase activity were performed using samples of equal protein concentration, previously determined by the method of Bradford (Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Bi ochem 1976; 72: 248-254). To control for differences in transfection efficiency, results of luciferase activity were corrected for ⁇ -galactosidase expression in the same transfection.
  • the cardiac myocytyes were cultured with CRH at a concentration of 10 "8 M in growth media for 24 hours. Approximately 1x10" cells were harvested in lOO ⁇ l of 2x concentrated SDS PAGE sample buffer for analysis of C/EBP family C/EBP ⁇ (NF-IL6) , C/EBP ⁇ (NF-IL6 ⁇ ) and NF-kB protein expression. Proteins separated by SDS-PAGE were subsequently transferred onto nitrocellulose membranes (Hybond C, Amersham, GB) and were then probed using antibodies to C/EBP ⁇ (NF-IL6) , C/EBP ⁇ (NF-IL6 ⁇ ) and NF-kB (all from Santa Cruz Biotechnology, Santa Cruz, CA) .
  • the - 2 1 - membranes were subsequently washed in PBS/0.05% Tween and incubated with a peroxidase conjugated rabbit anti-mouse IgG antibody (DAKO) at a dilution of 1/2000 followed by detection using an enhanced Chemiluminescence kit (ECL, Amersham) .
  • DAKO peroxidase conjugated rabbit anti-mouse IgG antibody
  • ECL enhanced Chemiluminescence kit
  • the relative protein levels were determined using densitometry (Bio Rad) normalising to the actin band on a duplicate Coomassie Brilliant Blue R250 (BDH) stained gel.
  • apoptosis TUNEL assay and flow cytometry
  • the number of apoptotic nuclei were assessed by using terminal transferase from calf thymus (Boehringer Mannhemim) and Fluorescein-12-2 ' -deoxy-uridine-5 ' - triphosphate.
  • Terminal transferase catalyses a template independent addition of deoxyribonucleotide triphosphate to the 3' -OH ends of double- and/or single-stranded DNA and has been used for assessment of apoptotic nuclei as described previously. Briefly cardiac myocytes were exposed to an ischaemic insult in conditioned media, in the presence and absence of 10 ⁇ 6 M Ucn and helical CRH
  • the cells were then returned to a normoxic environment for 2h and fixed in 4% paraformaldehyde for 30 min at 25°C and washed with PBS three times. Terminal deoxynucleotidyl transferase was added to the cells for 2h in a 37°C humidified incubator. After washing with PBS the cells were then imaged with fluorescent microscopy. The percentage of apoptotic nuclei is expressed as a percentage of total nuclei. For flow cytometry the cells were fixed in acetone-methanol (4:1), pelleted and treated with RNase for 15 minutes at 37°C. They where then stained with propidium iodide for 20 minutes at 37°C in the dark and analysed on a FACScan (Becton Dickinson, Mountain View, California, US) .
  • FACScan Becton Dickinson, Mountain View, California, US
  • the predicted sizes of the amplification products are 872 base pairs (G3PDH) , 196 base pairs (UcnRl) and 329 base pairs (UcnR2) .
  • Preconditioned media 28.05 + 3.21 treated cells (0% 0 2 , 5% C0 2 ) n 7 -24 -
  • cardiac myocytes showed increased expression of C/EBP transcription factors C/EBP ⁇ (NF- IL6), C/EBP ⁇ (NF-IL6 ⁇ ) and NF-kB after a two hour ischaemic insult.
  • the risk zone (R) was defined using fluorescent microspheres and the mfarct size (I) using TTC staining and the results are expressed as the %I/R.
  • the data therefore show that Ucn remains cardioprotective even when added after the ischaemic period. This suggests that Ucn and derivatives thereof may be useful in a clinical setting when administered after the onset of acute myocardial infarction.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'urocortine (Ucn) protège les cultures primaires de cellules myocardiques chez le rat contre des lésions ischémiques létales. Dans les cellules myocardiques, l'expression de l'Ucn augmente à la suite d'un accident ischémique. L'Ucn ou un équivalent cardioprotecteur dérivé de ce composé entre dans la fabrication d'un médicament utilisé pour le traitement de l'ischémie cardiaque.
PCT/GB1999/001056 1998-04-07 1999-04-07 Utilisation therapeutique de l'urocortine et de polypeptides analogues Ceased WO1999051261A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU33403/99A AU3340399A (en) 1998-04-07 1999-04-07 Use of urocortin and like polypeptides in therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9807504.7A GB9807504D0 (en) 1998-04-07 1998-04-07 Use of corticotropin releasing hormone and like polypeptides in therapy
GB9807504.7 1998-04-07

Publications (1)

Publication Number Publication Date
WO1999051261A1 true WO1999051261A1 (fr) 1999-10-14

Family

ID=10830024

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/001056 Ceased WO1999051261A1 (fr) 1998-04-07 1999-04-07 Utilisation therapeutique de l'urocortine et de polypeptides analogues

Country Status (3)

Country Link
AU (1) AU3340399A (fr)
GB (1) GB9807504D0 (fr)
WO (1) WO1999051261A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003097804A3 (fr) * 2002-05-16 2005-04-21 Wisconsin Alumni Res Found Sequences de type promoteur destinees a l'urocortine ii et utilisation associee
US7459427B2 (en) 2001-03-15 2008-12-02 Research Development Foundation Urocortin-III and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5177060A (en) * 1990-01-09 1993-01-05 Regents Of The University Of California Anti-inflammatory peptides and treatment to inhibit vascular leakage in injured tissues
WO1997000063A2 (fr) * 1995-06-13 1997-01-03 The Salk Institute For Biological Studies Peptides d'urocortine
WO1997032898A1 (fr) * 1996-03-06 1997-09-12 The Regents Of The University Of California Analogues anti-inflammatoires de crf, leur composition et leur emploi

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5177060A (en) * 1990-01-09 1993-01-05 Regents Of The University Of California Anti-inflammatory peptides and treatment to inhibit vascular leakage in injured tissues
WO1997000063A2 (fr) * 1995-06-13 1997-01-03 The Salk Institute For Biological Studies Peptides d'urocortine
WO1997032898A1 (fr) * 1996-03-06 1997-09-12 The Regents Of The University Of California Analogues anti-inflammatoires de crf, leur composition et leur emploi

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
OKOSI A (REPRINT) ET AL: "Expression and protective effects of urocortin in cardiac myocytes", NEUROPEPTIDES, (APR 1998) VOL. 32, NO. 2, PP. 167-171. PUBLISHER: CHURCHILL LIVINGSTONE, JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND. ISSN: 0143-4179., UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, DEPT CYST FIBROSIS, NATL HEART & LUNG INST, LONDON SW3 6LR, ENGLAND (Reprint);UNIV COLL, DEPT MOL PATHOL, LONDON, ENGLAND; UNIV GREENWICH, SCH CHEM & LIFE , XP002113409 *
PARKES, DAVID G. ET AL: "Cardiac inotropic actions of urocortin in conscious sheep", AM. J. PHYSIOL. (1997), 272(5, PT. 2), H2115-H2122, XP002113411 *
RICHTER R M (REPRINT) ET AL: "Cardiovascular and neuroendocrine profiles of urocortin - a potent regulator of the cardiovascular tone?", HYPERTENSION, (OCT 1997) VOL. 30, NO. 4, PP. 66-66. PUBLISHER: AMER HEART ASSOC, 7272 GREENVILLE AVENUE, DALLAS, TX 75231-4596. ISSN: 0194-911X., INST MOL PHARMACOL, BERLIN, GERMANY, XP002113410 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7459427B2 (en) 2001-03-15 2008-12-02 Research Development Foundation Urocortin-III and uses thereof
US8084413B2 (en) 2001-03-15 2011-12-27 Research Development Foundation Urocortin-III and uses thereof
US8445425B2 (en) 2001-03-15 2013-05-21 Research Development Foundation Urocortin-III and uses thereof
US8669092B2 (en) 2001-03-15 2014-03-11 Rsearch Development Foundation Urocortin-III and uses thereof
US9388229B2 (en) 2001-03-15 2016-07-12 Research Development Foundation Urocortin-III and uses thereof
WO2003097804A3 (fr) * 2002-05-16 2005-04-21 Wisconsin Alumni Res Found Sequences de type promoteur destinees a l'urocortine ii et utilisation associee
US7087385B2 (en) 2002-05-16 2006-08-08 Wisconsin Alumni Research Foundation Promoter sequences for urocortin II and the use thereof

Also Published As

Publication number Publication date
GB9807504D0 (en) 1998-06-10
AU3340399A (en) 1999-10-25

Similar Documents

Publication Publication Date Title
Brar et al. CRH-like peptides protect cardiac myocytes from lethal ischaemic injury
Chong et al. Stable overexpression of the constitutive form of heat shock protein 70 confers oxidative protection
James et al. A highly conserved insulin-like growth factor-binding protein (IGFBP-5) is expressed during myoblast differentiation.
Cardinaux et al. Vasoactive intestinal peptide, pituitary adenylate cyclase-activating peptide, and noradrenaline induce the transcription factors CCAAT/enhancer binding protein (C/EBP)-beta and C/EBP delta in mouse cortical astrocytes: involvement in cAMP-regulated glycogen metabolism
Brar et al. Urocortin protects against ischemic and reperfusion injury via a MAPK-dependent pathway
Oonk et al. Rat cholesterol side-chain cleavage cytochrome P-450 (P-450scc) gene. Structure and regulation by cAMP in vitro.
Stein et al. Cloning and expression of human steroid-sulfatase: Membrane topology, glycosylation, and subcellular distribution in BHK-21 cells
US7186694B2 (en) Leptin-related peptides
EP0309100B1 (fr) Emploi de l'amyline ou CGRP pour le traitement du diabète sucré
Bach et al. Recombinant human insulin-like growth factor (IGF)-binding protein-6 inhibits IGF-II-induced differentiation of L6A1 myoblasts
van Kesteren et al. Evolution of the vasopressin/oxytocin superfamily: characterization of a cDNA encoding a vasopressin-related precursor, preproconopressin, from the mollusc Lymnaea stagnalis.
Kislauskis et al. Mutually dependent response elements in the cis-regulatory region of the neurotensin/neuromedin N gene integrate environmental stimuli in PC12 cells
JP4568383B2 (ja) 血管形成の促進方法
US20050245441A1 (en) Use of compounds having gip activity for the treatment of disorders associated with abnormal loss of cells and/or for the treatment of obesity
CA2215387A1 (fr) Modulateurs du gene ob et methodes de depistage connexes
Ren et al. Somatostatin analog induces insulin-like growth factor binding protein-1 (IGFBP-1) expression in human hepatoma cells
HK1000934B (en) Use of amylin or cgrp for the treatment of diabetes mellitus
CA2343939A1 (fr) Genes et proteines predictifs et methodes therapeutiques destinees aux attaques, a l'hypertension, aux diabetes et a l'obesite
JP2001510984A (ja) 動物における摂食行動を調整するための哺乳動物メラノコルチンレセプター作用薬および拮抗薬を発見および使用するための方法および試薬
WO1996029405A9 (fr) MODULATEURS DU GENE ob ET PROCEDES DE CRIBLAGE A CET EFFET
CA2135813A1 (fr) Traitement de l'obesite
KR20040063906A (ko) 인간 3 릴랙신
CZ294983B6 (cs) Použití amylinu nebo agonisty amylinu pro výrobu léku k léčení nebo prevenci obezity u člověka
EP1573046B1 (fr) Hormone de liberation de l'hormone de croissance ti resistant aux proteases
Lin et al. Molecular cloning and expression of a type-two somatostatin receptor in goldfish brain and pituitary

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase